Research Analysts Issue Forecasts for ResMed Q3 Earnings

ResMed Inc. (NYSE:RMD - Free Report) - Equities research analysts at William Blair cut their Q3 2025 EPS estimates for ResMed in a research report issued to clients and investors on Monday, February 3rd. William Blair analyst M. Andrew now forecasts that the medical equipment provider will post earnings of $2.32 per share for the quarter, down from their prior estimate of $2.37. The consensus estimate for ResMed's current full-year earnings is $9.44 per share. William Blair also issued estimates for ResMed's FY2026 earnings at $10.23 EPS.

ResMed (NYSE:RMD - Get Free Report) last announced its earnings results on Thursday, January 30th. The medical equipment provider reported $2.43 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.29 by $0.14. ResMed had a net margin of 25.34% and a return on equity of 26.17%.

Several other analysts have also issued reports on the company. Stifel Nicolaus initiated coverage on ResMed in a report on Friday, December 13th. They set a "hold" rating and a $250.00 target price on the stock. KeyCorp upped their price objective on shares of ResMed from $266.00 to $280.00 and gave the stock an "overweight" rating in a research report on Friday, January 31st. StockNews.com raised shares of ResMed from a "hold" rating to a "buy" rating in a report on Tuesday, October 15th. Royal Bank of Canada upped their price target on shares of ResMed from $224.00 to $232.00 and gave the stock a "sector perform" rating in a report on Friday, October 25th. Finally, UBS Group raised shares of ResMed from a "hold" rating to a "strong-buy" rating in a research note on Friday, January 31st. One research analyst has rated the stock with a sell rating, six have issued a hold rating, seven have given a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, ResMed presently has an average rating of "Moderate Buy" and a consensus price target of $244.73.

ResMed Price Performance

NYSE:RMD traded up $1.62 during trading hours on Thursday, reaching $238.56. 388,038 shares of the company were exchanged, compared to its average volume of 995,205. The business has a 50 day moving average of $239.18 and a 200 day moving average of $237.81. ResMed has a 1-year low of $170.56 and a 1-year high of $263.05. The company has a debt-to-equity ratio of 0.13, a current ratio of 3.33 and a quick ratio of 2.29. The company has a market capitalization of $35.04 billion, a P/E ratio of 28.17, a P/E/G ratio of 1.57 and a beta of 0.70.

ResMed Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, March 20th. Stockholders of record on Thursday, February 13th will be issued a dividend of $0.53 per share. This represents a $2.12 annualized dividend and a dividend yield of 0.89%. The ex-dividend date of this dividend is Thursday, February 13th. ResMed's dividend payout ratio (DPR) is currently 25.03%.

Insider Activity

In other news, Director Peter C. Farrell sold 2,000 shares of the stock in a transaction dated Wednesday, December 4th. The stock was sold at an average price of $245.65, for a total value of $491,300.00. Following the completion of the sale, the director now owns 81,218 shares of the company's stock, valued at approximately $19,951,201.70. This represents a 2.40 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Justin Leong sold 6,160 shares of ResMed stock in a transaction that occurred on Friday, November 22nd. The stock was sold at an average price of $243.09, for a total value of $1,497,434.40. Following the completion of the transaction, the insider now directly owns 21,718 shares in the company, valued at approximately $5,279,428.62. This represents a 22.10 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 11,094 shares of company stock valued at $2,704,941 over the last quarter. 0.71% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the company. Howard Capital Management Inc. raised its stake in ResMed by 5.3% during the fourth quarter. Howard Capital Management Inc. now owns 900 shares of the medical equipment provider's stock worth $206,000 after buying an additional 45 shares during the last quarter. UMB Bank n.a. raised its position in shares of ResMed by 1.9% in the 3rd quarter. UMB Bank n.a. now owns 2,465 shares of the medical equipment provider's stock worth $602,000 after acquiring an additional 47 shares in the last quarter. Ascent Group LLC lifted its stake in shares of ResMed by 1.7% in the 3rd quarter. Ascent Group LLC now owns 2,924 shares of the medical equipment provider's stock valued at $714,000 after purchasing an additional 48 shares during the period. SkyView Investment Advisors LLC boosted its position in shares of ResMed by 2.0% during the 3rd quarter. SkyView Investment Advisors LLC now owns 2,610 shares of the medical equipment provider's stock valued at $637,000 after purchasing an additional 51 shares in the last quarter. Finally, Wedmont Private Capital grew its stake in ResMed by 2.6% during the fourth quarter. Wedmont Private Capital now owns 2,032 shares of the medical equipment provider's stock worth $475,000 after purchasing an additional 52 shares during the period. Institutional investors own 54.98% of the company's stock.

ResMed Company Profile

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.